Hisamitsu Pharmaceutical Co., Inc.
HTSUY · OTC
5/31/2025 | 2/28/2025 | 11/30/2024 | 8/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.42 | 0.15 | -0.17 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 33.72 | 17.22 | 26.76 | 0.27 |
| Quality | ||||
| ROIC | 0.80% | 1.66% | 1.12% | 172.88% |
| Gross Margin | 61.40% | 55.43% | 61.40% | 59.54% |
| Cash Conversion Ratio | 1.00 | 1.00 | 1.00 | 1.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.08% | 245.26% | 248.34% | 332.86% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -18.71 | -10.18 | -12.62 | -0.07 |
| Interest Coverage | 1,683.09 | 709.39 | 0.00 | 62,274.02 |
| Efficiency | ||||
| Inventory Turnover | 0.53 | 0.87 | 0.59 | 101.54 |
| Cash Conversion Cycle | 187.24 | 134.52 | 143.25 | 0.84 |